Konstantin Konstantinov
REPLIGENAbout Konstantin Konstantinov
Independent director at Repligen since 2022; age 67 as of the 2025 annual meeting. Currently Chief Technology Officer at Ring Therapeutics and an Operating Partner at Flagship Pioneering; previously CTO and EVP, Manufacturing & Process Sciences at Codiak BioSciences, led late‑stage bioprocess and technology development at Sanofi’s Boston hub, and spent 14 years at Bayer culminating as Head of Process Sciences. Holds a Ph.D. in Biochemical Engineering from Osaka University (post‑doc at DuPont/University of Delaware) and is recognized for pioneering end‑to‑end integrated continuous biomanufacturing; member of Repligen’s Scientific Advisory Board since March 2016 . The Board determined he is independent under Nasdaq standards .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ring Therapeutics | Chief Technology Officer | Current | Technology leadership in gene therapy modalities |
| Flagship Pioneering | Operating Partner | Current | Portfolio/scaling support across Flagship ventures |
| Codiak BioSciences | Chief Technology Officer; previously EVP, Manufacturing & Process Sciences | Prior to Ring | Built manufacturing and process sciences capabilities |
| Sanofi (Boston hub) | Lead for late‑stage bioprocess and technology development (cell banking to fill/finish/lyo) | Prior to Codiak | End‑to‑end late‑stage development oversight |
| Bayer (Berkeley, CA) | Head of Process Sciences | 14 years | Led process sciences; developed/commercialized mAbs, blood factors, enzymes |
| Repligen Scientific Advisory Board | Member | Since March 2016 | Scientific guidance to RGEN |
External Roles
| Organization | Role | Public Company? | Notes |
|---|---|---|---|
| Ring Therapeutics | Chief Technology Officer | No (private) | Current role |
| Flagship Pioneering | Operating Partner | Private firm | Current role |
| Other public company boards | — | — | None disclosed; “Other Public Boards” shows “–” for Konstantinov |
Board Governance
- Committee assignments: Member, Nominating & Corporate Governance (N&CG) Committee; 2024 N&CG members were Madaus (Chair), Konstantinov, and Pax; committee met 2 times in 2024 .
- Independence: Board classifies him as independent; all committee members are independent .
- Board/committee activity: Board met 6 times in 2024; Audit met 6; Compensation met 4; N&CG met 2 .
- Attendance: Company states all directors attended 100% of Board and applicable committee meetings during their service in 2024, except one unnamed director who attended 1 of 2 applicable committee meetings .
- Executive sessions: Independent directors hold executive sessions at each Board meeting .
- ESG oversight: N&CG Chair oversees ESG program and reporting; committee reports to the Board on ESG matters (Konstantinov serves on N&CG) .
Fixed Compensation (Non‑Employee Director; FY2024)
| Component | Amount | Notes |
|---|---|---|
| Board annual cash retainer | $60,000 | Standard non‑employee director retainer |
| N&CG Committee member retainer | $5,000 | N&CG member (non‑chair) fee |
| Total cash fees (reported) | $65,000 | Matches Form 14A director comp table for Konstantinov |
Performance Compensation (Equity; FY2024)
| Grant Type | Grant Date | Quantity | Exercise/Grant Price | Grant Date Fair Value | Vesting |
|---|---|---|---|---|---|
| Stock options | 5/16/2024 | 1,376 | $171.03 | $116,759 | Annual director equity vests in full on earlier of 1st anniversary or next annual meeting, subject to service |
| RSUs | 5/16/2024 | 701 | — | $119,892 | Same schedule as above |
| Annual equity policy | — | — | — | Target $240,000 | 50% RSUs / 50% options for non‑chair directors; new‑director initial awards vest over 3 years; sale events accelerate vesting |
2024 total reported compensation: $301,651 (cash $65,000; stock awards $119,892; option awards $116,759) .
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Current public company directorships | None disclosed for Konstantinov |
| Committee interlocks | No interlocks disclosed in 2025 proxy; compensation committee members are independent |
| Related‑party transactions | Company reports no related‑party transactions >$120,000 since Jan 1, 2024 involving any director/officer; Audit Committee reviews/approves such transactions |
Expertise & Qualifications
- Deep bioprocess development and manufacturing leadership across Bayer (14 years), Sanofi late‑stage development, Codiak CTO, and Ring CTO; 60+ peer‑reviewed papers and 15+ patents/applications .
- Recognized pioneer in integrated continuous biomanufacturing; Ph.D. in Biochemical Engineering (Osaka University) .
Equity Ownership
| Metric | Detail |
|---|---|
| Total beneficial ownership | 5,670 shares (less than 1% of outstanding) |
| Of which: options exercisable within 60 days | 4,450 shares via stock options (within 60 days of March 7, 2025) |
| Unvested RSUs (as of 12/31/2024) | 701 RSUs outstanding as non‑employee director |
| Shares outstanding (basis for %) | 56,148,556 shares outstanding as of March 7, 2025 |
| Hedging/pledging | Company policy prohibits hedging and pledging without Audit Committee pre‑approval; no pledges disclosed for Konstantinov |
| Ownership guidelines | Directors must hold 4x annual cash retainer within 5 years; all directors comply or are on track |
Director Compensation (FY2024) – Detail
| Item | Amount |
|---|---|
| Fees earned or paid in cash | $65,000 |
| Stock awards (RSUs) | $119,892 |
| Option awards | $116,759 |
| Total | $301,651 |
Governance Assessment
- Board effectiveness and independence: Independent director with highly relevant technical expertise; serves on N&CG, the committee overseeing board composition and ESG practices .
- Engagement/attendance: Company disclosed strong attendance across directors in 2024, with only one unnamed exception; 6 Board meetings and regular executive sessions of independent directors support effective oversight .
- Alignment and incentives: Director pay structure balanced between modest cash retainer and time‑based equity (RSUs/options) with clear vesting; equity retainer targeted at $240k aligns directors with shareholders while avoiding performance metric gaming for oversight roles .
- Conflicts/related‑party risk: No related‑party transactions disclosed involving Konstantinov; insider trading policy prohibits hedging/pledging without approval; stock ownership guidelines in place and met/on‑track .
- Shareholder signals: Prior say‑on‑pay vote (2023) approved by ~94% of votes cast, signaling general investor support for compensation programs; company outlines ongoing shareholder engagement .
RED FLAGS: None disclosed specific to Konstantinov. Monitor for potential ecosystem overlaps given his operating roles (Ring/Flagship) in adjacent modalities; however, company reports no related‑party transactions >$120k and affirms independence .